🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
549,04 USD
Máx. histórico
558,88
5 días
Split 2:1 del 24/08/2000
Caída desde máximo
-1,76%
Rango 52 semanas
406,67 – 568,67
Variación hoy
+3,44%
Cierre anterior
530,76
Rango de hoy
527,38 – 550,77
Volumen hoy
1.810.311
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 36,82 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 11 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 01/02/2019 | 190,92 | 193,03 | 189,92 | 191,52 | +0,32% | 1,63% | 892.800 |
| 31/01/2019 | 187,17 | 190,98 | 186,86 | 190,91 | +2,06% | 2,20% | 900.800 |
| 30/01/2019 | 185,84 | 187,92 | 184,50 | 187,05 | +0,36% | 1,84% | 1.385.900 |
| 29/01/2019 | 188,16 | 188,26 | 184,70 | 186,38 | -0,91% | 1,89% | 1.024.500 |
| 28/01/2019 | 188,94 | 188,98 | 185,76 | 188,09 | -0,74% | 1,70% | 1.513.500 |
| 25/01/2019 | 188,16 | 190,39 | 186,27 | 189,50 | +1,57% | 2,19% | 1.404.800 |
| 24/01/2019 | 189,64 | 190,23 | 186,47 | 186,58 | -1,74% | 1,98% | 1.825.300 |
| 23/01/2019 | 194,67 | 195,20 | 187,78 | 189,89 | -2,06% | 3,81% | 2.043.000 |
| 22/01/2019 | 193,48 | 195,81 | 192,39 | 193,88 | -0,42% | 1,77% | 2.003.900 |
| 18/01/2019 | 192,63 | 194,78 | 189,41 | 194,70 | +2,19% | 2,79% | 2.150.100 |
| 17/01/2019 | 185,77 | 191,42 | 184,71 | 190,52 | +2,35% | 3,61% | 1.605.900 |
| 16/01/2019 | 186,21 | 188,34 | 184,13 | 186,15 | -0,28% | 2,26% | 2.251.200 |
| 15/01/2019 | 184,37 | 186,76 | 183,06 | 186,68 | +1,51% | 2,01% | 1.330.500 |
| 14/01/2019 | 186,71 | 186,99 | 183,78 | 183,91 | -2,26% | 1,72% | 1.962.000 |
| 11/01/2019 | 184,62 | 188,86 | 183,43 | 188,16 | +1,14% | 2,94% | 2.222.600 |
| 10/01/2019 | 181,85 | 186,09 | 180,26 | 186,03 | +2,05% | 3,21% | 1.988.200 |
| 09/01/2019 | 179,14 | 182,70 | 178,25 | 182,30 | +2,31% | 2,48% | 2.298.500 |
| 08/01/2019 | 177,00 | 178,41 | 174,72 | 178,19 | +1,33% | 2,08% | 1.653.200 |
| 07/01/2019 | 173,05 | 176,78 | 170,87 | 175,85 | +1,82% | 3,42% | 1.294.600 |
| 04/01/2019 | 165,90 | 173,31 | 164,90 | 172,70 | +5,48% | 5,07% | 1.874.500 |
| 03/01/2019 | 165,83 | 169,32 | 163,18 | 163,73 | -0,21% | 3,70% | 1.690.900 |
| 02/01/2019 | 161,21 | 165,14 | 160,95 | 164,08 | -0,98% | 2,60% | 1.465.400 |
| 31/12/2018 | 162,80 | 166,21 | 162,00 | 165,71 | +2,66% | 2,59% | 1.375.400 |
| 28/12/2018 | 163,52 | 164,84 | 160,38 | 161,42 | -0,59% | 2,73% | 966.700 |
| 27/12/2018 | 158,95 | 162,58 | 156,27 | 162,37 | +0,33% | 3,97% | 1.485.000 |
| 26/12/2018 | 152,98 | 161,87 | 152,40 | 161,84 | +6,54% | 6,19% | 1.638.400 |
| 24/12/2018 | 155,40 | 158,47 | 151,80 | 151,91 | -2,93% | 4,29% | 1.158.200 |
| 21/12/2018 | 161,94 | 165,07 | 156,30 | 156,50 | -2,98% | 5,42% | 2.677.600 |
| 20/12/2018 | 158,52 | 163,48 | 157,70 | 161,30 | +1,66% | 3,65% | 2.213.300 |
| 19/12/2018 | 163,04 | 164,42 | 156,30 | 158,66 | -2,92% | 4,98% | 1.877.600 |